Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference166 articles.
1. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N et al. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717–727.
2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127–137.
3. Akita RW, Sliwkowski MX . (2003). Preclinical studies with Erlotinib (Tarceva). Semin Oncol 30 (3 Suppl 7): 15–24.
4. Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky EK, Hudis C et al. (2002). Open-label phase II multicenter trial of ZD1839 (‘Iressa’) in patients with advanced breast cancer. Breast Cancer Res Treat 76: S33 #20.
5. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C et al. (2006). Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259–267.
Cited by
154 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献